BIOLEADERS CORPORATION

Location not on file

Oncologygene editingGrant-only

What changed

Study registered, no phase assigned: Video Conference-Based Brief Cognitive Behavioral Therapy for Suicidal High-Risk Outpatients With Mood Disorders

6w agoTrial registeredJun 3, 2026Source filing (opens the source filing in a new tab)

Momentum

76no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
Jun 15, 2026
Revision Total Knee Arthroplasty · NOT_YET_RECRUITING · sponsor: The Methodist Hospital Research Institute · IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA
ClinicalTrials.gov · NCT07283068 (opens the source filing in a new tab)
Trial
NA registered
Mar 16, 2026
Suicidal Ideation and Behaviors, Suicide Attempt, Cognitive Behavioral Therapy · ACTIVE_NOT_RECRUITING · sponsor: Hyung Keun Park · Video Conference-Based Brief Cognitive Behavioral Therapy for Suicidal High-Risk Outpatients With Mood Disorders
ClinicalTrials.gov · NCT07395817 (opens the source filing in a new tab)
Grant
R21 · $440k · non-dilutive
Jul 1, 2025
STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI PARK, YUNGKI · NINDS · award ends Jun 30, 2027 · Systematic discovery of Olig2 upstream regulators for central nervous system myelination
NIH RePORTER · NIH RePORTER 11135005 (opens the source filing in a new tab)
Grant
R21 · $194k · non-dilutive
Apr 1, 2025
JOHNS HOPKINS UNIVERSITY · PI KANG, HIJEE · NIDCD · award ends Mar 31, 2028 · Neural dynamics in auditory cortex during implicit learning of complex sounds
NIH RePORTER · NIH RePORTER 11121297 (opens the source filing in a new tab)
Grant
UG1 · $543k · non-dilutive
Mar 1, 2025
WASHINGTON UNIVERSITY · PI JAMES, AIMEE S · NCI · award ends Feb 28, 2026 · Administrative Supplement to Building equity in cancer screening through research: The Siteman Catchment CSRN Hub
NIH RePORTER · NIH RePORTER 11267550 (opens the source filing in a new tab)
Patent
Patent granted
Jan 7, 2025
assignee: BIOLEADERS CORPORATION · SURFACE EXPRESSION VECTOR USING POLY-GAMMA-GLUTAMATE SYNTHETIC GENE DERIVED FROM STRAIN IN BACILLUS, AND METHOD FOR EXPRESSING PROTEIN ON SURFACE OF MICROORGANISM, USING SAME
USPTO · US 12188026 (opens the source filing in a new tab)
Grant
R01 · $1.0M · non-dilutive
Jun 9, 2023
UNIVERSITY OF CALIFORNIA-IRVINE · PI JAMES, ANTHONY A. · NIAID · award ends May 31, 2026 · Impact of gene-drive systems for population modification on malaria vector mosquitoes
NIH RePORTER · NIH RePORTER 11086802 (opens the source filing in a new tab)
Grant
K08 · $265k · non-dilutive
Jul 11, 2022
BRIGHAM AND WOMEN'S HOSPITAL · PI PARK, KO UN · NCI · award ends Jun 30, 2027 · Implementation of Operative Standards in Cancer Surgery to Improve Patient Outcomes
NIH RePORTER · NIH RePORTER 11125790 (opens the source filing in a new tab)
Patent
Patent assigned
Dec 17, 2020
assignee: BIOLEADERS CORPORATION · SURFACE EXPRESSION VECTOR USING POLY-GAMMA-GLUTAMATE SYNTHETIC GENE DERIVED FROM STRAIN IN BACILLUS, AND METHOD FOR EXPRESSING PROTEIN ON SURFACE OF MICROORGANISM, USING SAME
USPTO · US 12188026 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator KANG, HIJEE is named on this company's filings"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the trial record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the patent record at 0.70{"reasons":["name similarity 100%","shared principal investigator / founder"]}
new_entity links the patent record at 0.24{"reasons":["no candidate cleared the review threshold"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Video Conference-Based Brief Cognitive Behavioral Therapy for Suicidal High-Risk Outpatients With Mood Disorders
6w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA
2mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R21 · $0.4M · Systematic discovery of Olig2 upstream regulators for central nervous system myelination
Jun 2025New grantSource (opens the source filing in a new tab)
NIH UG1 · $0.5M · Administrative Supplement to Building equity in cancer screening through research: The Siteman Catchment CSRN Hub
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH K08 · $0.3M · Implementation of Operative Standards in Cancer Surgery to Improve Patient Outcomes
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $1.0M · Impact of gene-drive systems for population modification on malaria vector mosquitoes
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Neural dynamics in auditory cortex during implicit learning of complex sounds
Mar 2025New grantSource (opens the source filing in a new tab)
Patent granted · SURFACE EXPRESSION VECTOR USING POLY-GAMMA-GLUTAMATE SYNTHETIC GENE DERIVED FROM STRAIN IN BACILLUS, AND METHOD FOR EXPRESSING PROTEIN ON SURFACE OF MICROORGANISM, USING SAME
Jan 2025Patent grantedSource (opens the source filing in a new tab)
Patent assigned · SURFACE EXPRESSION VECTOR USING POLY-GAMMA-GLUTAMATE SYNTHETIC GENE DERIVED FROM STRAIN IN BACILLUS, AND METHOD FOR EXPRESSING PROTEIN ON SURFACE OF MICROORGANISM, USING SAME
Dec 2020Patent assignedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

NA registered

NA registered

R21 · $440k · non-dilutive

R21 · $194k · non-dilutive

UG1 · $543k · non-dilutive

Patent granted

R01 · $1.0M · non-dilutive

K08 · $265k · non-dilutive

Patent assigned